These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

682 related items for PubMed ID: 18084695

  • 1. Update on the Japanese guidelines for the use of infliximab and etanercept in rheumatoid arthritis.
    Koike R, Takeuchi T, Eguchi K, Miyasaka N, Japan College of Rheumatology.
    Mod Rheumatol; 2007; 17(6):451-8. PubMed ID: 18084695
    [Abstract] [Full Text] [Related]

  • 2. [Treatment guidelines for the use of biologics in rheumatoid arthritis; present and future].
    Miyasaka N, Koike R.
    Nihon Rinsho; 2007 Jul; 65(7):1169-78. PubMed ID: 17642228
    [Abstract] [Full Text] [Related]

  • 3. [Pneumonia, pneumocystis pneumonia].
    Koike R, Harigai M.
    Nihon Rinsho; 2007 Jul; 65(7):1314-20. PubMed ID: 17642249
    [Abstract] [Full Text] [Related]

  • 4. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents.
    Strangfeld A, Listing J, Herzer P, Liebhaber A, Rockwitz K, Richter C, Zink A.
    JAMA; 2009 Feb 18; 301(7):737-44. PubMed ID: 19224750
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. The infectious profiles of anti-tumor necrosis factor agents in a Thai population: a retrospective study a the university-based hospital.
    Suwannalai P, Auethavekiat P, Udomsubpayakul U, Janvitayanujit S.
    Int J Rheum Dis; 2009 Jul 18; 12(2):118-24. PubMed ID: 20374328
    [Abstract] [Full Text] [Related]

  • 8. Lack of adverse effect of anti-tumor necrosis factor-α biologics in treatment of rheumatoid arthritis: 5 years follow-up.
    Dewedar AM, Shalaby MA, Al-Homaid S, Mahfouz AM, Shams OA, Fathy A.
    Int J Rheum Dis; 2012 Jun 18; 15(3):330-5. PubMed ID: 22709496
    [Abstract] [Full Text] [Related]

  • 9. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register.
    Dixon WG, Watson K, Lunt M, Hyrich KL, Silman AJ, Symmons DP, British Society for Rheumatology Biologics Register.
    Arthritis Rheum; 2006 Aug 18; 54(8):2368-76. PubMed ID: 16868999
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Etanercept maintains the clinical benefit achieved by infliximab in patients with rheumatoid arthritis who discontinued infliximab because of side effects.
    Iannone F, Trotta F, Montecucco C, Giacomelli R, Galeazzi M, Matucci-Cerinic M, Ferri C, Cutolo M, Maria Bambara L, Triolo G, Ferraccioli G, Valentini G, Lapadula G, GISEA (Gruppo Italiano per lo Studio delle Early Arthritis).
    Ann Rheum Dis; 2007 Feb 18; 66(2):249-52. PubMed ID: 16837489
    [Abstract] [Full Text] [Related]

  • 13. Etanercept, infliximab, and leflunomide in established rheumatoid arthritis: clinical experience using a structured follow up programme in southern Sweden.
    Geborek P, Crnkic M, Petersson IF, Saxne T, South Swedish Arthritis Treatment Group.
    Ann Rheum Dis; 2002 Sep 18; 61(9):793-8. PubMed ID: 12176803
    [Abstract] [Full Text] [Related]

  • 14. TNF blockade in the treatment of rheumatoid arthritis: infliximab versus etanercept.
    Mikuls TR, Moreland LW.
    Expert Opin Pharmacother; 2001 Jan 18; 2(1):75-84. PubMed ID: 11336570
    [Abstract] [Full Text] [Related]

  • 15. Evidence for differential acquired drug resistance to anti-tumour necrosis factor agents in rheumatoid arthritis.
    Finckh A, Simard JF, Gabay C, Guerne PA, SCQM physicians.
    Ann Rheum Dis; 2006 Jun 18; 65(6):746-52. PubMed ID: 16339288
    [Abstract] [Full Text] [Related]

  • 16. [Efficacy and adverse events of etanercept in patients with rheumatoid arthritis: reports of postmarketing surveillance in Japan].
    Eguchi K.
    Nihon Rinsho; 2007 Jul 18; 65(7):1259-66. PubMed ID: 17642241
    [Abstract] [Full Text] [Related]

  • 17. Patients' perceptions of treatment with anti-TNF therapy for rheumatoid arthritis: a qualitative study.
    Marshall NJ, Wilson G, Lapworth K, Kay LJ.
    Rheumatology (Oxford); 2004 Aug 18; 43(8):1034-8. PubMed ID: 15150436
    [Abstract] [Full Text] [Related]

  • 18. Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population.
    Ollendorf DA, Klingman D, Hazard E, Ray S.
    Clin Ther; 2009 Apr 18; 31(4):825-35. PubMed ID: 19446156
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report.
    Gómez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD, BIOBADASER Group.
    Arthritis Rheum; 2003 Aug 18; 48(8):2122-7. PubMed ID: 12905464
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 35.